Intra-Cellular Therapies Inc (BSP:I2TC34)
R$ 84.24 0 (0%) Market Cap: 52.81 Bil Enterprise Value: 46.88 Bil PE Ratio: 0 PB Ratio: 7.72 GF Score: 32/100

Intra-Cellular Therapies Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 12:30PM GMT
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Hello, Good morning, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan.

Welcome to the 48th Annual Healthcare Conference. I'm really pleased to be kicking off the conference this morning with Intra-Cellular. I'm joined by the company's Chairman and Chief Executive Officer, Dr. Sharon Mates. I'm going to turn it over to her for a presentation, and then we're going to go into Q&A after that. (Operator Instructions)

So with that out of the way, Sharon, let me turn it over to you.

Sharon Mates
Intra-Cellular Therapies, Inc. - Co-Founder, Chairman, CEO & President

Great. Thanks so much, Jess. And here we are again, virtually. I wish you and everyone a happy New Year. And with that, I will start our presentation. Before I do, to tell you, I'm joined here today by Mark Neumann, our Chief Commercial Officer; Larry Hineline, our Chief Financial Officer; and Suresh Durgam, our Chief Medical Officer.

Our presentation today will contain

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot